Accepted for Publication: April 23, 2015.
Published Online: June 29, 2015. doi:10.1001/jamaneurol.2015.1099.
Study concept and design: Quiroz, Tariot, Dickerson, Sperling, Lopera, Reiman.
Acquisition, analysis, or interpretation of data: Quiroz, Schultz, Chen, Protas, Brickhouse, Fleisher, Langbaum, Thiyyagura, Fagan, Shah, Muniz, Arboleda-Velasquez, Munoz, Garcia, Acosta-Baena, Giraldo, Tirado, Ramírez, Dickerson, Sperling, Reiman.
Drafting of the manuscript: Quiroz, Chen, Reiman.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Quiroz, Schultz, Chen, Protas, Thiyyagura, Shah.
Obtained funding: Tariot, Lopera, Reiman.
Administrative, technical, or material support: Schultz, Chen, Protas, Thiyyagura, Fagan, Shah, Muniz, Sperling, Lopera.
Study supervision: Quiroz, Lopera, Reiman.
Conflict of Interest Disclosures: Dr Quiroz has served as a consultant for MedAvante. Dr Fleisher has served as a consultant for Eli Lilly, Avid, Merck, Grifols, Quintiles, and Biogen. Dr Fleisher has been an invited speaker for Quintiles, Avid, and Lilly CME grant programs. Dr Fleisher has data and safety monitoring board membership with the National Institute on Aging (NIA), Merck, and Pfizer; grant funding from NIA and Eli Lilly; and has had studies sponsored by Merck, Roche, Genentech, Pfizer, Avanir, Takeda, Lilly, Bristol-Myers Squibb, Baxter, Neuroptix, and Wyeth. Dr Fleisher is a full-time employee of Eli Lilly as of April 2014. Dr Fagan is a member of the scientific advisory boards of IBL International and Roche, as well as a consultant for AbbVie. Dr Tariot has received consulting fees from Abbott Laboratories, AC Immune, Adamas, Allergan, Avanir, Boehringer-Ingelheim, Chase Pharmaceuticals, Chiesi, Eisai Inc, Elan, MedAvante, Merz Pharma, Neuroptix, Novartis, Otsuka, sanofi, Schering-Plough, and Worldwide Clinical Trials. Dr Tariot has also received consulting fees and research support from AstraZeneca, Avid, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Eli Lilly, Medivation, Merck and Company, Pfizer Inc, Roche, Toyama, and Wyeth Laboratories, as well as research support from Baxter Healthcare Corp, Functional Neuromodulation (f[nm]), GE, and Targacept. Dr Tariot has stock options in MedAvante and Adamas and holds patents related to biomarkers of Alzheimer disease. Dr Sperling has received consulting fees from Genentech, Roche, Isis, and Janssen, as well as research support from Eli Lilly, Avid, Janssen, and Eisai. Dr Reiman has received research funding from Avid and has a paid consultation role for Eli Lilly. No other disclosures were reported.
Funding/Support: This study was supported by grants from an anonymous foundation (Drs Reiman and Lopera), the Banner Alzheimer’s Foundation, the Nomis Foundation, the National Institutes of Health Office of the Director (DP5OD019833 [Dr Quiroz]), the National Institute on Aging (R01 AG031581 [Dr Reiman], P30 AG19610 [Dr Reiman], RF1AG041705 [Drs Reiman, Tariot, and Lopera], and 2UF1 AG032438 [Dr Fagan]), the National Eye Institute (EY021624 [Dr Arboleda-Velasquez]), and Colciencias-Colombia (1115-408-20512 and 1115-545-31651 [Dr Lopera]).
Role of the Funder/Sponsor: This study was designed and conducted by investigators from the Massachusetts General Hospital, Banner Alzheimer’s Institute, and Universidad de Antioquia. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the Hospital Pablo Tobon Uribe staff for their help with data acquisition. We thank the PSEN1 Colombian families for contributing their valuable time and effort, without which this study would not have been possible.